SECURITIES AND EXCHANGE COMMISSION
                                   Washington, D.C.


          LITIGATION RELEASE NO.   16072 / February 25, 1999

          SECURITIES AND EXCHANGE COMMISSION v. FUTREX, INC., FUTREX
          MEDICAL INSTRUMENTATION, INC., AND ROBERT D. ROSENTHAL, No.
          1:96CV02192 (RWR)(D.D.C.)


                                SEC OBTAINS FINAL JUDGMENTS
                          CONCLUDING FUTREX SECURITIES FRAUD CASE

               The Securities and Exchange Commission has obtained a final
          judgment against Futrex, Inc., Futrex Medical Instrumentation,
          Inc. (jointly referred to as "Futrex"), and Robert D. Rosenthal,
          Futrex’s chairman of the board, chief executive officer,
          president, and treasurer, in a fraud case arising from Futrex’s
          private placement of securities in 1994 and abortive initial
          public offering in 1995.  Without admitting or denying the
          Commission’s allegations, the defendants consented to entry of
          the judgment, which enjoins them from violating Section 17(a) of
          the Securities Act of 1933, Section 10(b) of the Securities
          Exchange Act of 1934, and Rule 10b-5 thereunder, and orders
          Rosenthal to pay a $50,000 civil penalty.

               The Commission’s complaint, filed on September 23, 1996,
          alleged that the defendants, in connection with Futrex’s 1994
          private placement and 1995 abortive initial public offering, made
          materially false and misleading statements concerning Futrex’s
          "Dream Beam" product, a hand-held laboratory instrument that
          purportely could measure a person’s blood glucose level by
          passing infrared light through his or her finger.  Among other
          things, the complaint alleged that the defendants fraudulently
          made unsupportable claims about the effectiveness of the Dream
          Beam, failed to disclose adverse results from studies of the
          Dream Beam, and staged deceptive demonstrations of the Dream Beam
          for prospective investors.  (See also Litigation Rel. No. 15061
          (Sept. 23, 1996)).